{"id":956522,"date":"2026-04-30T08:06:49","date_gmt":"2026-04-30T12:06:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy\/"},"modified":"2026-04-30T08:06:49","modified_gmt":"2026-04-30T12:06:49","slug":"solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-showcase-a-large-presence-at-the-29th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy\/","title":{"rendered":"Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy"},"content":{"rendered":"
\n

\n – Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters –\u00a0<\/em>\n <\/p>\n

CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the \u201cCompany\u201d or \u201cSolid\u201d), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29th<\/sup> Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11-15, 2026, in Boston, MA.<\/p>\n

Solid Biosciences will deliver its largest number of presentations for the Company, reflecting the growing breadth and depth of Solid\u2019s scientific efforts spanning clinical development, next-generation delivery technologies, capsid engineering and scalable manufacturing.<\/p>\n

\u201cWith 16 Solid-led presentations, ASGCT 2026 marks an important meeting for the Company and reflects our growing leadership in next-generation precision genetic medicine,\u201d said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. \u201cThe number and diversity of presentations we will be sharing underscore how far our organization has progressed in three short years, in addition to the scientific rigor we\u2019re applying across discovery, development, manufacturing and clinical translation. From advanced platform and delivery technology engineering to updates from our clinical programs, this body of work reflects both the ambition of our team and the increasing maturity of our science.\u201d<\/p>\n

\n Oral Presentations<\/strong>\n <\/p>\n

    \n
  1. \n Title:<\/strong> Update on the INSPIRE DUCHENNE Phase 1\/2 Study of the Next-Generation Microdystrophin Gene Therapy Candidate SGT-003 for Duchenne Muscular Dystrophy
    Session:<\/strong> In vivo clinical trials in eye and muscle disorders
    Presentation ID:<\/strong> 502
    Date\/Time:<\/strong> May 15, 3:30pm ET
    Presenter:<\/strong> Kevin Flanigan, MD, Advisor Consultant & Researcher, Nationwide Children\u2019s Hospital and Principal Investigator in the Phase 1\/2 INSPIRE DUCHENNE clinical trial<\/li>\n
  2. \n Title:<\/strong> Efficacy and Safety of a Novel Investigational AAV FXN Gene Therapy (SGT-212) for the Treatment of Friedreich\u2019s Ataxia
    Session:<\/strong> Neurologic diseases V
    Presentation ID:<\/strong> 353
    Date\/Time:<\/strong> May 14, 10:30am ET
    Presenter:<\/strong> Brandon Chan, PhD, Discovery & Translational Development, Scientific Lead<\/li>\n
  3. \n Title:<\/strong> Development and Implementation of a High Yield and Scalable Manufacturing Process for Adeno-Associated Virus (AAV) Production
    Session:<\/strong> Scale-up, scale-out, formulation, supply chains, quality, and logistics I
    Presentation ID:<\/strong> 246
    Date\/Time:<\/strong> May 13, 4:00pm ET
    Presenter:<\/strong> Ben Wright, Vice President, Head of Process Development<\/li>\n
  4. \n Title:<\/strong> Boosting rAAV Yield in HEK293 Cells Through Multi-Mechanism Strategies
    Session:<\/strong> AAV transfection improvements: Scaling and titers
    Presentation ID:<\/strong> 320
    Date\/Time:<\/strong> May 14, 10:30am ET
    Presenter:<\/strong> Xiaofei E, PhD, Director, Molecular Therapeutics<\/li>\n
  5. \n Title:<\/strong> Utilizing Machine Learning and Mechanistic Understanding to Appreciate the Impact of pH, Dissolved Oxygen, and pCO\u2082 on Upstream AAV Yield and Product Quality
    Session: <\/strong>AAV critical quality attributes
    Presentation ID:\u00a0<\/strong>263
    Date\/Time: <\/strong>May 14, 8:00am ET
    Presenter:<\/strong> Neil Templeton, PhD, Director, Upstream Process Development<\/li>\n<\/ol>\n

    \n Poster Presentations<\/strong>\n <\/p>\n

      \n
    1. \n Title:\u00a0<\/strong>Novel Pharmacokinetic Effects of POLARIS-101\u2122\u00a0(AAV-SLB101), Solid Biosciences\u2019 Rationally Designed, Next-Generation Capsid
      Presentation ID:<\/strong> 3385
      Presenter:<\/strong> Patrick Gonzalez, PhD, Vice President, Head of Clinical Science<\/li>\n
    2. \n Title:<\/strong> SGT-003 Gene Therapy Restores DAPC Stability and Improves Muscle Integrity in Duchenne Muscular Dystrophy
      Presentation ID:<\/strong> 2365
      Presenter:<\/strong> Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development<\/li>\n
    3. \n Title:<\/strong> A Novel AAV Gene Therapy Strategy to Correct Calcium Dysregulation in Catecholaminergic Polymorphic Ventricular Tachycardia
      Presentation ID:<\/strong> 1429
      Presenter:<\/strong> Meghan Soustek-Kramer, PhD, Principal Scientist and Scientific Lead, Discovery & Translational Development<\/li>\n
    4. \n Title:<\/strong> Systemic Delivery of Human TNNT2 Gene Therapy Using the Novel Capsid POLARIS-101\u2122\u00a0(AAV-SLB101) Improves Cardiac Function in the TNNT2 R141W Knock-in Mouse Model of Dilated Cardiomyopathy
      Presentation ID:<\/strong> 3430
      Presenter:<\/strong> Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development<\/li>\n
    5. \n Title:<\/strong> Systemic Administration of a Rationally Engineered Vector (POLARIS-101\u2122\u00a0[AAV-SLB101]) Leads to Successful Transduction of Non-Human Primate Tissues in the Presence of Neutralizing Antibodies
      Presentation ID:<\/strong> 3397
      Presenter:<\/strong> Kruti Patel, PhD, Associate Director and Scientific Lead, Discovery & Translational Development<\/li>\n
    6. \n Title:<\/strong> Lower POLARIS-101TM<\/sup> (AAV-SLB101) Cross-Reactive Antibodies in Elevidys-Treated Patients
      Presentation ID:<\/strong> 3382
      Presenter:<\/strong> Marla Bazile, Principal Associate Scientist, R&D<\/li>\n
    7. \n Title:<\/strong> Small Molecule Induced G2\/M Arrest Boosts Recombinant AAV Production and Preserves High Quality
      Presentation ID:\u00a0<\/strong>3146
      Presenter:<\/strong> Xiaofei E, PhD, Director, Molecular Therapeutics<\/li>\n
    8. \n Title:<\/strong> Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity
      Presentation ID:<\/strong> 2010
      Presenter:<\/strong> Jie Tan, PhD, Director, Predictive Sciences<\/li>\n
    9. \n Title:<\/strong> Connecting Changes in AAV Capsid Protein Charge Species to In Vitro Protein Expression
      Presentation ID: <\/strong>2216
      Presenter:<\/strong> Jonathan Hill, PhD, Principal Scientist<\/li>\n
    10. \n Title:<\/strong> Impact of Full vs. Empty AAV Capsids on Vector Potency
      Presentation ID:<\/strong> 2221
      Presenter:<\/strong> Cristiano Vieira, PhD, Senior Scientist, Analytical<\/li>\n
    11. \n Title:<\/strong> Identifying Sources of Library Preparation Artifacts in AAV Vectors with SMRT Sequencing
      Presentation ID:<\/strong> 1219
      Presenter:<\/strong> Sarah Tong, Senior Associate Scientist, Analytical Development<\/li>\n<\/ol>\n

      Additionally, Armatus Bio will present a poster highlighting POLARIS-101\u2122\u2019s utility in Facioscapulohumeral muscular dystrophy (FSHD) animal models:<\/p>\n